Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
PDF) The unfinished symphony: golimumab therapy for anti-TNF refractory Crohn's disease
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Adalimumab | ECCO E-Guide
PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Frontiers | Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical M
Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
Neel Heerasing (@gastrodr_nh) / Twitter
ECCO-EFCCA Patient Guidelines on Crohn's Disease (CD)
